The neglected tropical disease treatment market size has grown strongly in recent years. It will grow from $3.36 billion in 2024 to $3.57 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. This historical growth is attributed to a greater government focus on disease elimination programs, expanding public-private partnerships for drug donations, rising pharmaceutical donations from global manufacturers, increasing research into low-cost antiparasitic therapies, and growing investments in vaccine and diagnostic development.
The neglected tropical disease treatment market size is expected to see strong growth in the next few years. It will grow to $4.52 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. Key growth drivers in the forecast period include the expanded use of digital tools for disease monitoring, a growing pipeline of new drugs and vaccines, rising concerns about antimicrobial resistance, enhanced cross-border collaboration for disease control, and the influence of climate change on disease spread. Notable trends expected in the forecast period include the development of localized treatment strategies, affordable vaccine platforms, integration with primary healthcare services, expansion of disease surveillance networks, and innovations in vector control technologies.
The increasing prevalence of infectious diseases is anticipated to drive the growth of the neglected tropical disease treatment market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which can spread from one person to another either directly or indirectly. This rise in infectious diseases is primarily attributed to increased global travel, which accelerates the transmission of pathogens across borders. Neglected tropical disease treatment plays a crucial role by offering targeted therapies that help control and eliminate the spread of these diseases. These treatments are particularly beneficial in vulnerable communities, where they improve public health outcomes by reducing disease burden and preventing long-term disabilities. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England increased to 4,850 in 2023, a 10.7% rise from 4,380 cases in 2022. This trend highlights how the growing prevalence of infectious diseases is fueling the demand for neglected tropical disease treatments.
Companies in the neglected tropical disease treatment market are emphasizing strategic investments to strengthen research and development, broaden global access, and advance innovative therapies. These investments contribute significantly to market growth by supporting advanced research, encouraging collaborations, and expediting the creation of affordable and effective treatments for underserved populations. For instance, in June 2022, Novartis AG, a pharmaceutical corporation based in Switzerland, committed $250 million toward combating neglected tropical diseases (NTDs) and malaria. This funding aims to make treatments more accessible in low-income regions and to support the development of new therapies for these diseases.
In August 2022, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical company, and Aurigene Pharmaceutical Services Limited, also based in India, collaborated with the Drugs for Neglected Diseases initiative (DNDi) to develop, manufacture, and commercialize new treatments for neglected tropical diseases. This partnership is intended to speed up the development of affordable and accessible therapies, addressing the unmet medical needs in low- and middle-income countries. The DNDi, headquartered in Switzerland, is a non-profit organization dedicated to developing effective and affordable treatments for neglected tropical diseases.
Major players in the neglected tropical disease treatment market are Pfizer Inc., Johnson And Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Eisai Co. Ltd., Shionogi And Co. Ltd., Dr. Reddy`s Laboratories Ltd, Cipla Ltd., Eiken Chemical Company Ltd, LifeArc, Atomwise Inc., and Medicines Development for Global Health Ltd.
Asia Pacific was the largest region in the neglected tropical disease treatment market in 2024. The regions covered in neglected tropical disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the neglected tropical disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Neglected tropical disease (NTD) treatment refers to medical interventions aimed at controlling, eliminating, or eradicating a group of infectious diseases that predominantly impact impoverished populations in tropical and subtropical areas. The primary objective of these treatments is to reduce the disease burden, prevent disability, and enhance the quality of life within affected communities.
The primary drug classes utilized in treating neglected tropical diseases include anti-parasitic agents, antifungals, antibiotics, and others. Anti-parasitic agents are substances or treatments intended to prevent, kill, or eliminate parasites that infect humans, animals, or plants. These treatments address a range of diseases such as leishmaniasis, schistosomiasis, lymphatic filariasis, Chagas disease, African trypanosomiasis, and others. The drugs are administered either orally or parenterally and are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. These treatments cater to multiple end users, such as hospitals, specialty clinics, homecare settings, and more.
The neglected tropical disease treatment market research report is one of a series of new reports that provides neglected tropical disease treatment market statistics, including the neglected tropical disease treatment industry's global market size, regional shares, competitors with the neglected tropical disease treatment market share, detailed neglected tropical disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neglected tropical disease treatment market. This neglected tropical disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The neglected tropical disease treatment market consists of revenues earned by entities by providing services such as mass drug administration, disease surveillance, diagnostic testing, patient care and management, health education, and vector control programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The neglected tropical disease (NTD) treatment market also includes sales of diagnostic kits, vaccines, insecticides, and medical devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The neglected tropical disease treatment market size is expected to see strong growth in the next few years. It will grow to $4.52 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. Key growth drivers in the forecast period include the expanded use of digital tools for disease monitoring, a growing pipeline of new drugs and vaccines, rising concerns about antimicrobial resistance, enhanced cross-border collaboration for disease control, and the influence of climate change on disease spread. Notable trends expected in the forecast period include the development of localized treatment strategies, affordable vaccine platforms, integration with primary healthcare services, expansion of disease surveillance networks, and innovations in vector control technologies.
The increasing prevalence of infectious diseases is anticipated to drive the growth of the neglected tropical disease treatment market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which can spread from one person to another either directly or indirectly. This rise in infectious diseases is primarily attributed to increased global travel, which accelerates the transmission of pathogens across borders. Neglected tropical disease treatment plays a crucial role by offering targeted therapies that help control and eliminate the spread of these diseases. These treatments are particularly beneficial in vulnerable communities, where they improve public health outcomes by reducing disease burden and preventing long-term disabilities. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England increased to 4,850 in 2023, a 10.7% rise from 4,380 cases in 2022. This trend highlights how the growing prevalence of infectious diseases is fueling the demand for neglected tropical disease treatments.
Companies in the neglected tropical disease treatment market are emphasizing strategic investments to strengthen research and development, broaden global access, and advance innovative therapies. These investments contribute significantly to market growth by supporting advanced research, encouraging collaborations, and expediting the creation of affordable and effective treatments for underserved populations. For instance, in June 2022, Novartis AG, a pharmaceutical corporation based in Switzerland, committed $250 million toward combating neglected tropical diseases (NTDs) and malaria. This funding aims to make treatments more accessible in low-income regions and to support the development of new therapies for these diseases.
In August 2022, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical company, and Aurigene Pharmaceutical Services Limited, also based in India, collaborated with the Drugs for Neglected Diseases initiative (DNDi) to develop, manufacture, and commercialize new treatments for neglected tropical diseases. This partnership is intended to speed up the development of affordable and accessible therapies, addressing the unmet medical needs in low- and middle-income countries. The DNDi, headquartered in Switzerland, is a non-profit organization dedicated to developing effective and affordable treatments for neglected tropical diseases.
Major players in the neglected tropical disease treatment market are Pfizer Inc., Johnson And Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Eisai Co. Ltd., Shionogi And Co. Ltd., Dr. Reddy`s Laboratories Ltd, Cipla Ltd., Eiken Chemical Company Ltd, LifeArc, Atomwise Inc., and Medicines Development for Global Health Ltd.
Asia Pacific was the largest region in the neglected tropical disease treatment market in 2024. The regions covered in neglected tropical disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the neglected tropical disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Neglected tropical disease (NTD) treatment refers to medical interventions aimed at controlling, eliminating, or eradicating a group of infectious diseases that predominantly impact impoverished populations in tropical and subtropical areas. The primary objective of these treatments is to reduce the disease burden, prevent disability, and enhance the quality of life within affected communities.
The primary drug classes utilized in treating neglected tropical diseases include anti-parasitic agents, antifungals, antibiotics, and others. Anti-parasitic agents are substances or treatments intended to prevent, kill, or eliminate parasites that infect humans, animals, or plants. These treatments address a range of diseases such as leishmaniasis, schistosomiasis, lymphatic filariasis, Chagas disease, African trypanosomiasis, and others. The drugs are administered either orally or parenterally and are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. These treatments cater to multiple end users, such as hospitals, specialty clinics, homecare settings, and more.
The neglected tropical disease treatment market research report is one of a series of new reports that provides neglected tropical disease treatment market statistics, including the neglected tropical disease treatment industry's global market size, regional shares, competitors with the neglected tropical disease treatment market share, detailed neglected tropical disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neglected tropical disease treatment market. This neglected tropical disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The neglected tropical disease treatment market consists of revenues earned by entities by providing services such as mass drug administration, disease surveillance, diagnostic testing, patient care and management, health education, and vector control programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The neglected tropical disease (NTD) treatment market also includes sales of diagnostic kits, vaccines, insecticides, and medical devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Neglected Tropical Disease Treatment Market Characteristics3. Neglected Tropical Disease Treatment Market Trends And Strategies4. Neglected Tropical Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Neglected Tropical Disease Treatment Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Neglected Tropical Disease Treatment Market34. Recent Developments In The Neglected Tropical Disease Treatment Market
5. Global Neglected Tropical Disease Treatment Growth Analysis And Strategic Analysis Framework
6. Neglected Tropical Disease Treatment Market Segmentation
7. Neglected Tropical Disease Treatment Market Regional And Country Analysis
8. Asia-Pacific Neglected Tropical Disease Treatment Market
9. China Neglected Tropical Disease Treatment Market
10. India Neglected Tropical Disease Treatment Market
11. Japan Neglected Tropical Disease Treatment Market
12. Australia Neglected Tropical Disease Treatment Market
13. Indonesia Neglected Tropical Disease Treatment Market
14. South Korea Neglected Tropical Disease Treatment Market
15. Western Europe Neglected Tropical Disease Treatment Market
16. UK Neglected Tropical Disease Treatment Market
17. Germany Neglected Tropical Disease Treatment Market
18. France Neglected Tropical Disease Treatment Market
19. Italy Neglected Tropical Disease Treatment Market
20. Spain Neglected Tropical Disease Treatment Market
21. Eastern Europe Neglected Tropical Disease Treatment Market
22. Russia Neglected Tropical Disease Treatment Market
23. North America Neglected Tropical Disease Treatment Market
24. USA Neglected Tropical Disease Treatment Market
25. Canada Neglected Tropical Disease Treatment Market
26. South America Neglected Tropical Disease Treatment Market
27. Brazil Neglected Tropical Disease Treatment Market
28. Middle East Neglected Tropical Disease Treatment Market
29. Africa Neglected Tropical Disease Treatment Market
30. Neglected Tropical Disease Treatment Market Competitive Landscape And Company Profiles
31. Neglected Tropical Disease Treatment Market Other Major And Innovative Companies
35. Neglected Tropical Disease Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Neglected Tropical Disease Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on neglected tropical disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for neglected tropical disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neglected tropical disease treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Class: Anti-Parasite; Antifungal; Antibiotics; Other Drugs Class2) By Disease Type: Leishmaniasis; Schistosomiasis; Lymphatic Filariasis; Chagas Disease; African Trypanosomiasis; Other Disease Types
3) By Route of Administration: Oral; Parenteral
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By End User: Hospital; Specialty Clinics; Homecare Settings; Other End Users
Subsegments:
1) By Anti-Parasite: Anthelmintics; Antiprotozoals; Antimalarials; Ectoparasiticides2) By Antifungal: Azoles; Polyenes; Allylamines; Echinocandins
3) By Antibiotics: Tetracyclines; Macrolides; Rifamycins; Sulfonamides
4) By Other Drug Classes: Antivirals; Corticosteroids; Combination Therapies; Supportive Treatments
Key Companies Profiled: Pfizer Inc.; Johnson And Johnson; Merck And Co. Inc.; AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Johnson And Johnson
- Merck And Co. Inc.
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Sanofi S.A.
- AstraZeneca PLC
- Abbott Laboratories
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc.
- Eisai Co. Ltd.
- Shionogi And Co. Ltd.
- Dr. Reddy`s Laboratories Ltd
- Cipla Ltd.
- Eiken Chemical Company Ltd
- LifeArc
- Atomwise Inc.
- Medicines Development for Global Health Ltd.